Summit Therapeutics (NASDAQ: SMMT) pulls planned stock sale amid markets

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Summit Therapeutics Inc. has withdrawn its previously announced proposed underwritten public offering of securities, effective June 10, 2026, citing market conditions. Because the offering has been terminated, no securities will be sold under that proposed transaction. The update is provided as a Regulation FD disclosure and is not treated as a filed report for liability purposes under Section 18 of the Exchange Act.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Key Terms

underwritten public offering, Emerging growth company, Regulation FD Disclosure, Section 18 of the Exchange Act, +1 more

5 terms

underwritten public offering financial

"it has withdrawn its previously announced proposed underwritten public offering of securities"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

Emerging growth company regulatory

"Emerging growth company Summit Therapeutics Inc."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Regulation FD Disclosure regulatory

"the information set forth under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act"

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

Section 18 of the Exchange Act regulatory

"shall not be deemed “filed” for purposes of Section 18 of the Exchange Act"

Securities Act of 1933 regulatory

"nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

06/11/2026 - 07:44 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 10, 2026


Summit Therapeutics Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-36866	37-1979717
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

601 Brickell Key Drive, Suite 1000, Miami, FL		33131
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (305) 203-2034


Not applicable
(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.01 par value per share	SMMT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 7.01			Other Events.

Summit Therapeutics Inc. (the “Company”) announced that effective June 10, 2026 it has withdrawn its previously announced proposed underwritten public offering of securities due to market conditions.

As a result of such termination, no securities will be sold pursuant to the proposed underwritten public offering. This Current Report on Form 8-K is not an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

In accordance with General Instruction B.2 of Form 8-K, the information set forth under this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


	SUMMIT THERAPEUTICS INC.


Date: June 11, 2026	By:	/s/ Manmeet S. Soni
		Chief Operating Officer, Chief Financial Officer and Director
		(Principal Financial Officer)

Source: View Original Filing on SEC EDGAR

FAQ

What did Summit Therapeutics Inc. (SMMT) announce in this 8-K?

Summit Therapeutics Inc. announced that it has withdrawn its previously announced proposed underwritten public offering of securities. The company states this decision was made due to market conditions and confirms that no securities will be sold under that proposed offering.

Why did Summit Therapeutics (SMMT) withdraw its proposed underwritten offering?

Summit Therapeutics withdrew its previously announced proposed underwritten public offering of securities due to market conditions. The company did not provide additional detail in this disclosure but clearly states that the market environment prompted the decision to terminate the proposed offering.

Will Summit Therapeutics (SMMT) sell any securities under the withdrawn offering?

No, Summit Therapeutics will not sell any securities under the withdrawn proposed underwritten public offering. The company explicitly states that, as a result of the termination, no securities will be sold pursuant to that specific proposed offering of securities.

Is this Summit Therapeutics (SMMT) disclosure considered filed under Section 18?

No, the company specifies that the information under Item 7.01 is furnished, not filed, for purposes of Section 18 of the Exchange Act. This means it is not subject to Section 18 liabilities nor automatically incorporated into Securities Act or Exchange Act filings.

What SEC item does Summit Therapeutics (SMMT) use for this announcement?

Summit Therapeutics uses Item 7.01, Regulation FD Disclosure, for this announcement. The company notes that, under General Instruction B.2, information furnished under this item is not deemed filed or subject to Section 18 liabilities unless specifically incorporated by reference elsewhere.

Does the withdrawn Summit Therapeutics (SMMT) offering affect existing securities?

The disclosure only states that the proposed underwritten public offering has been terminated and that no securities will be sold under it. It does not describe any changes to existing outstanding securities or other capital structure elements in this particular announcement.

Filing Exhibits & Attachments

4 documents